Sun Pharma beats street estimates in Q3 with net profit up 16%

The Mumbai-based drugmaker said its total sales grew 15.1% year-on-year. ₹15,469 crore. Total revenue from operations increased by 13.4% annually ₹15,520.5 crore, the company stated in its regulatory filing.

The company offset the decline in Revlimid sales by delivering steady revenue growth across its branded businesses in India and emerging markets and global innovative sales.

A. Bloomberg Survey predicted drugmaker’s revenue would rise ₹14,792 crore with profit after tax ₹3,035 crore for the quarter.

The pharmaceutical company’s earnings before interest, taxes, depreciation and amortization (EBITDA) for this quarter were as follows: ₹4,948.5 crore, an increase of 23.4%, while the margin increased from 29.3% to 31.9% in the previous year.

“Our results for the quarter show well-rounded growth across all businesses, prominently led by our Branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has further expanded with the launch of Unloxcyt in the US and the launch of Ilumya in India,” Managing Director Kirti Ganorkar said in a statement.

Region based sales

Sun Pharma’s U.S. generic sales increased 0.6% year over year to $477 million. The company said innovative medicines continued to grow, offsetting the decline in its generics business. US sales accounted for approximately 27.5% of total consolidated sales.

Global innovative medicine sales totaled $423 million in 3Q26; this includes a milestone revenue of $55 million. Former landmark global innovative drug sales increased 13.2% and accounted for 21.2% of sales.

Sun Pharma’s innovative sales surpassed generic sales in the U.S. for the first time in the September quarter, signaling the company’s focus on new drugs.

There is uncertainty about the potential impact of most favored nation (MFN) drug pricing norms implemented in the United States. Under MFN drug pricing norms, drugmakers must match the lowest price offered for a drug in other developed countries, part of the Trump administration’s push to localize healthcare and make it cheaper for Americans.

Sun Pharma has not yet disclosed any potential effects.

India sales increased by 16.2% ₹4,999 crore, outpacing the growth of the overall Indian pharmaceutical market. India sales accounted for 32.3% of total sales.

According to Pharmarack’s MAT December 2025 report, Sun’s market share in India increased from 8.1% to 8.4%.

Earlier this month, Sun Pharma announced that it had received approval from the central regulator to launch semaglutide for weight control and plans to launch it once its patent expires in March.

Sun Pharma’s share price closed on: ₹1,595.00 on NSE on Friday, rising marginally to 0.36%.